Shares of Organon & Co. (NYSE:OGN) have earned a consensus rating of “Hold” from the nine brokerages that are covering the stock, Marketbeat.com reports. Five investment analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12-month price target among brokers that have covered the stock in the last year is $40.29.
OGN has been the subject of a number of recent research reports. Morgan Stanley upped their price target on Organon & Co. from $33.00 to $35.00 and gave the stock an “equal weight” rating in a research report on Monday, August 16th. Evercore ISI initiated coverage on Organon & Co. in a research note on Thursday, June 10th. They issued an “outperform” rating on the stock. Citigroup boosted their price objective on Organon & Co. from $35.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, August 18th. The Goldman Sachs Group began coverage on Organon & Co. in a research report on Thursday, June 3rd. They set a “neutral” rating and a $35.00 target price on the stock. Finally, Bank of America assumed coverage on Organon & Co. in a research report on Wednesday, September 1st. They issued a “buy” rating and a $43.00 price objective on the stock.
In other Organon & Co. news, Director Ma. Fatima Francisco bought 3,000 shares of the company’s stock in a transaction on Thursday, August 19th. The stock was acquired at an average price of $33.79 per share, for a total transaction of $101,370.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.
OGN stock traded down $0.25 on Thursday, reaching $33.29. 27,676 shares of the company were exchanged, compared to its average volume of 3,177,992. Organon & Co. has a 12 month low of $27.25 and a 12 month high of $38.75. The company has a fifty day simple moving average of $32.52.
Organon & Co. (NYSE:OGN) last issued its earnings results on Thursday, August 12th. The company reported $1.72 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.49 by $0.23.
The firm also recently disclosed a quarterly dividend, which was paid on Monday, September 13th. Stockholders of record on Monday, August 23rd were given a $0.28 dividend. The ex-dividend date of this dividend was Friday, August 20th. This represents a $1.12 annualized dividend and a dividend yield of 3.36%.
Organon & Co. Company Profile
Organon & Co, a science-based pharmaceutical company, develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive.
Further Reading: The risks of owning bonds
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.